KRAS and MAPK1 gene amplification in type II ovarian carcinomas

International Journal of Molecular Sciences

Volumn 14, Issue 7, 2013, Pages 13748-13762

  Rahman, Mohammed Tanjimur ^a   Nakayama, Kentaro ^a   Rahman, Munmun ^a   Katagiri, Hiroshi ^a   Katagiri, Atsuko ^a   Ishibashi, Tomoka ^a   Ishikawa, Masako ^a   Sato, Emi ^a   Iida, Kouji ^a   Nakayama, Naomi ^a   Ishikawa, Noriyuki ^a   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Gene amplification; KRAS; MAPK1; MEK inhibitor; Survival; Type II ovarian carcinoma

Indexed keywords

CARBOPLATIN; DOCETAXEL; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PLATINUM COMPLEX; KRAS PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; CYTOREDUCTIVE SURGERY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MAPK1 GENE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR GENE; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; MALE; METABOLISM; MORTALITY; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL RATE;

EID: 84879949593     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140713748     Document Type: Article

References (24)

1. Wingo, P.A.; Tong, T.; Bolden, S. Cancer statistics 1995. CA Cancer J. Clin. 1995, 45, 8-30.
2. Hoskins, W.J.; McGuire, W.P.; Brady, M.F.; Homesley, H.D.; Creasman, W.T.; Berman, M.; Ball, H.; Berek, J.S. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 1994, 170, 974-979, discussion 979-980.
3. Ozols, R.F.; Bundy, B.N.; Greer, B.E.; Fowler, J.M.; Clarke-Pearson, D.; Burger, R.A.; Mannel, R.S.; DeGeest, K.; Hartenbach, E.M.; Baergen, R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J. Clin. Oncol. 2003, 21, 3194-3200.
4. McGuire, W.P.; Hoskins, W.J.; Brady, M.F.; Kucera, P.R.; Partridge, E.E.; Look, K.Y.; Clarke-Pearson, D.L.; Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334, 1-6.
5. Kurman, R.J.; Shih, le-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm. Hum. Pathol. 2011, 42, 918-931.
6. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609-615.
7. Mizumoto, Y.; Kyo, S.; Mori, N.; Sakaguchi, J.; Ohno, S.; Maida, Y.; Hashimoto, M.; Takakura, M.; Inoue, M. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci. 2007, 98, 652-658.
8. Nakayama, N.; Nakayama, K.; Yeasmin, S.; Ishibashi, M.; Katagiri, A.; Iida, K.; Fukumoto, M.; Miyazaki, K. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br. J. Cancer 2008, 99, 2020-2028.
9. Cho, K.R.; Shih, le-M. Ovarian cancer. Annu. Rev. Pathol. 2009, 4, 287-313.
10. Nakayama, K.; Nakayama, N.; Kurman, R.J.; Cope, L.; Pohl, G.; Samuels, Y.; Velculescu, V.E.; Wang, T.L.; Shih, le-M. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther. 2006, 5, 779-785.
11. Small, G.W.; Shi, Y.Y.; Higgins, L.S.; Orlowski, R.Z. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 2007, 67, 4459-4466.
12. Vicent, S.; Garayoa, M.; López-Picazo, J.M.; Lozano, M.D.; Toledo, G.; Thunnissen, F.B.; Manzano, R.G.; Montuenga, L.M. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin. Cancer Res. 2004, 10, 3639-3649.
13. Kelly, K.; Chu, Y. The Regulation of MAP Kinase Pathways by MAP Kinase Phosphatases. In Signaling Networks and Cell Cycle Control; Gutkind, J.S., Ed.; Humana Press: Totowa, NJ, USA, 2000; pp. 165-182.
14. Tanaka, Y.; Terai, Y.; Tanabe, A.; Sasaki, H.; Sekijima, T.; Fujiwara, S.; Yamashita, Y.; Kanemura, M.; Ueda, M.; Sugita, M. et al. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol. Ther. 2011, 11, 50-57.
15. Lanitis, E.; Dangaj, D.; Hagemann, I.S.; Song, D.G.; Best, A.; Sandaltzopoulos, R.; Coukos, G.; Powell, D.J., Jr. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One 2012, 7, e49829.
16. Nakayama, K.; Nakayama, N.; Jinawath, N.; Salani, R.; Kurman, R.J.; Shih, le-M.; Wang, T.L. Amplicon profiles in ovarian serous carcinomas. Int. J. Cancer 2007, 120, 2613-2617.
17. Scott, M.; Hall, P.A. Prognostic and predictive factors. Methods Mol. Med. 2004, 97, 1-11.
18. Weinstein, I.B.; Joe, A. Oncogene addiction. Cancer Res. 2008, 68, 3077-3080.
19. Nakayama, N.; Nakayama, K.; Shamima, Y.; Ishikawa, M.; Katagiri, A.; Iida, K.; Miyazaki, K. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010, 116, 2621-2634.
20. Iida, K.; Nakayama, K.; Rahman, M.T.; Rahman, M.; Ishikawa, M.; Katagiri, A.; Yeasmin, S.; Otsuki, Y.; Kobayashi, H.; Nakayama, S. et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma; making the EGFR pathway a novel therapeutic target. Br. J. Cancer 2011, 105, 420-427.
21. Wagner, P.L.; Stiedl, A.C.; Wilbertz, T.; Petersen, K.; Scheble, V.; Menon, R.; Reischl, M.; Mikut, R.; Rubin, M.A.; Fend, F. et al. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer 2011, 74, 118-123.
22. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W. et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-954.
23. Singer, G.; Oldt, R., 3rd.; Cohen, Y.; Wang, B.G.; Sidransky, D.; Kurman, R.J.; Shih, le-M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 2003, 95, 484-486.
24. Nakayama, K.; Miyazaki, K.; Kanzaki, A.; Fukumoto, M.; Takebayashi, Y. Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol. Rep. 2001, 8, 1285-1287.